Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Heart-focused healthy food additive supplier Provexis booked a full-year loss after rising revenue was offset by R&D spending.
Pre-tax losses for the year through March amounted to £0.53m, compared to losses of £0.47m on-year.
Revenue rose 37% to £0.32m, offset by higher R&D spending primarily due to blood-pressure-lowering patent application costs.
At 9:47am: (LON:PXS) Provexis PLC share price was 0p at 0.3p